FDA just lifted the long-standing “black box” warning on most hormone replacement therapy (HRT) for menopause—a major shift after more than 20 years of fear and confusion around estrogen and progesterone therapies.
In this segment, Dr. Jon Mendelsohn, Medical Director of Advanced Vitality, and women’s health specialist Donna Abdelnour break down what this change really means for women in perimenopause and menopause:
What the black box warning was and why it scared so many women away from treatment.
How new data has clarified the real risks vs. benefits of menopause hormone therapy
Why timing matters (usually starting within 10 years of menopause or before age 60)
Differences between systemic HRT (patches, pills, gels) and local vaginal estrogen
Who might not be a good candidate for HRT
Non-hormonal options for hot flashes, night sweats, sleep issues, and more
If you’re struggling with hot flashes, night sweats, brain fog, low libido, weight changes, or mood shifts, this conversation can help you understand your options and prepare better questions for your own provider.
🩺 Want to talk with our team at Advanced Vitality?
We offer personalized, evidence-based hormone therapy and telemedicine consults for women in midlife and beyond.
👉 Next steps:
Write down your top 3 menopause symptoms.
Note when your last period was and any major health history (blood clots, cancer, stroke, etc.).
Schedule a consult to review whether HRT or non-hormonal options are right for you.
Chapters (you can adjust times later):
00:00 Introduction & what changed with the black box warning
00:45 Why the warning was added in the first place
02:00 Updated science on risks & benefits of HRT
03:30 Who is a good candidate for hormone therapy?
05:00 Options beyond pills: patches, creams, vaginal estrogen
06:30 Non-hormonal options for menopause symptoms
08:00 How to talk to your provider & next steps
Disclaimer:
This video is for educational purposes only and is not individual medical advice. Always talk with your own healthcare provider before starting, changing, or stopping any medication.
Summary:
The video discusses the recent lifting of the FDA’s “black box” warning on hormone replacement therapy (HRT) products for menopause, a significant change after over 20 years of caution (0:00).
Key points from the discussion include:
- The original warning (0:45): The “black box” warning was implemented in 2002 based on flawed studies (the Hurst trial and Women’s Health Initiative—WHI study) that suggested HRT increased the risk of cardiovascular disease, certain cancers (breast and endometrial), stroke, and dementia. These studies included an older population already prone to such risks (0:45–1:09).
- Updated scientific understanding (2:00): Newer data indicates that for suitable candidates, HRT is beneficial. Hormones are now understood to be cardioprotective, osteoprotective, and brain protective. This means HRT can decrease the risk of cardiovascular disease, cognitive issues, osteoporosis, and can improve body composition, fat distribution, and symptoms like hot flashes, night sweats, mood swings, sleep issues, skin problems, joint pain, hair loss, and overall quality of life and sexual health (1:10–1:40).
- Candidate suitability (3:30): HRT is not for everyone (1:55). Guidelines suggest it is typically suitable for women under 60 years old or within 10 years of menopause. An entire generation of women unfortunately missed out on HRT due to previous fears (2:24–2:45).
- Treatment options (5:00): The safest routes for hormone replacement are bioidentical and transdermal (patches, creams, intramuscular injections), which are considered safer than oral medications (2:00–2:12). The discussion also touches on testosterone therapy for women, which can improve vitality but may not be covered by insurance (3:23–3:37).
- Next steps for women (8:00): Women considering HRT should consult their doctor and undergo an extensive lab panel to evaluate their hormonal and endocrine health (2:54–3:15).
Recent Comments